January 28th, 2022
The request comes after the regulatory agency made headlines for previously requesting 55 and then 75 years to fully release the information it used to approve Pfizer’s increasingly-mandated COVID jab.
The U.S. Food and Drug Administration (FDA) has once again requested permission to hold off on releasing the data it used to approve Pfizer’s COVID-19 shots for widespread distribution despite a court order requiring them to begin publishing 55,000 pages of documents per month starting in March.
Meanwhile, Pfizer has attempted to insert itself into the matter in an effort to protect its interests.
The FDA’s request to continue hiding the crucial safety data from consumers comes as COVID-19 jabs, including those produced by Pfizer, are increasingly mandated across the U.S. and the globe for participation in many aspects of society.
Attorney Aaron Siri, who filed a Freedom of Information Act (FOIA) lawsuit against the FDA in August on behalf of a coalition of researchers and scientists to demand the full release of the documents, wrote about the developments in a Substack post on Wednesday.
According to Siri, the FDA “has now asked the Court to make the public wait until May for it to start producing 55,000 pages per month and, even then, claims it may not be able to meet this rate.”
Meanwhile, “[a]s the FDA tries to obtain months of delay, guess who just showed [up] in the lawsuit?” Siri asked rhetorically, adding, “Yep, Pfizer.”
FDA tells Court must delay first 55,000 pages until at least May. FDA’s excuse? Lack of resources. Maybe spend less taxpayer money fighting transparency!
And Pfizer has now moved to join the lawsuit claiming it wants to help expedite. 😂
— Aaron Siri (@AaronSiriSG) January 26, 2022
The regulatory body’s renewed efforts to stall publication of the documents and Pfizer’s arrival on the scene come after the FDA raised eyebrows last year by requesting decades to fully release the data it had reviewed before authorizing Pfizer’s COVID-19 injections.
Facing legal pressure, however, in November the FDA released its first batch of documents, a scant 91 pages that, nonetheless contained data suggesting that tens of thousands of serious adverse events and more than 1,200 deaths had been reported in the first three months after Pfizer’s drug was cleared by the FDA under an Emergency Use Authorization (EUA).
Then, earlier this month, a U.S. district judge rejected the FDA’s request to continue delaying the release of the data, ordering the regulatory body to publish the documents at a rate of 55,000 pages per month beginning in March rather than the 500 pages per month initially requested.